[go: up one dir, main page]

DK3060229T3 - Stabile, vandige antistofformuleringer - Google Patents

Stabile, vandige antistofformuleringer Download PDF

Info

Publication number
DK3060229T3
DK3060229T3 DK14855343.1T DK14855343T DK3060229T3 DK 3060229 T3 DK3060229 T3 DK 3060229T3 DK 14855343 T DK14855343 T DK 14855343T DK 3060229 T3 DK3060229 T3 DK 3060229T3
Authority
DK
Denmark
Prior art keywords
stable
antibody formulations
water
water antibody
formulations
Prior art date
Application number
DK14855343.1T
Other languages
English (en)
Inventor
William Leach
Rachael Lewus
James Mcgivney
Kelcy Newell
Kevin Douglas Stewart
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3060229T3 publication Critical patent/DK3060229T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
DK14855343.1T 2013-10-24 2014-10-23 Stabile, vandige antistofformuleringer DK3060229T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361895143P 2013-10-24 2013-10-24
PCT/US2014/061997 WO2015061584A1 (en) 2013-10-24 2014-10-23 Stable, aqueous antibody formulations

Publications (1)

Publication Number Publication Date
DK3060229T3 true DK3060229T3 (da) 2021-10-11

Family

ID=52993565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14855343.1T DK3060229T3 (da) 2013-10-24 2014-10-23 Stabile, vandige antistofformuleringer

Country Status (23)

Country Link
US (4) US20150118249A1 (da)
EP (2) EP3892288A1 (da)
JP (3) JP6483673B2 (da)
KR (3) KR102109053B1 (da)
CN (4) CN105611938B (da)
AU (4) AU2014339984B2 (da)
BR (1) BR112016008576B1 (da)
CA (1) CA2926089C (da)
CY (1) CY1125697T1 (da)
DK (1) DK3060229T3 (da)
ES (1) ES2893861T3 (da)
HR (1) HRP20211371T1 (da)
HU (1) HUE055919T2 (da)
LT (1) LT3060229T (da)
MX (2) MX388893B (da)
PL (1) PL3060229T3 (da)
PT (1) PT3060229T (da)
RS (1) RS62419B1 (da)
RU (2) RU2763787C2 (da)
SG (2) SG11201603206UA (da)
SI (1) SI3060229T1 (da)
SM (1) SMT202100580T1 (da)
WO (1) WO2015061584A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
US9159537B2 (en) * 2012-05-03 2015-10-13 University Of Notre Dame Du Lac Method for analyzing sample components
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗mcam抗體及相關使用方法
CN105611938B (zh) * 2013-10-24 2024-12-31 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
EP3116911B8 (en) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP2018530540A (ja) * 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗mcam抗体の使用
EP4606820A3 (en) * 2015-11-30 2025-10-29 Medimmune, LLC Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
TWI656882B (zh) * 2016-08-10 2019-04-21 南韓商賽特瑞恩股份有限公司 穩定的液體抗流感病毒抗體醫藥調配物
WO2018075818A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
AU2019329686A1 (en) 2018-08-27 2020-12-03 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
AU2020251627A1 (en) * 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof
TW202126688A (zh) 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
WO2021124793A1 (ja) * 2019-12-16 2021-06-24 ニプロ株式会社 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
CN111024963A (zh) * 2019-12-27 2020-04-17 桂林英美特生物技术研究所 一种液体稳定、抗冰冻的免疫比浊法载脂蛋白b单试剂
WO2021182874A1 (ko) * 2020-03-13 2021-09-16 삼성바이오에피스 주식회사 안정성이 증진된 액상 약제학적 조성물
CN113769081A (zh) * 2020-06-10 2021-12-10 三生国健药业(上海)股份有限公司 一种稳定的高浓度抗人il-5单克隆抗体液体制剂
WO2022025030A1 (ja) * 2020-07-28 2022-02-03 中外製薬株式会社 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤
KR20230121797A (ko) * 2020-12-17 2023-08-21 아스트라제네카 아베 항-il5r 항체 제형
WO2026027944A1 (en) * 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
ES2178635T3 (es) 1990-11-09 2003-01-01 Stephen D Gillies Inmunoconjugados de citoquinas.
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE69633973T2 (de) * 1995-09-11 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
EP1539212A4 (en) * 2002-07-12 2007-05-02 Medarex Inc METHOD AND COMPOSITIONS FOR PREVENTING OXIDATIVE DEGRADATION OF PROTEINS
CA2526983C (en) * 2003-05-26 2010-08-10 Woo In Baik Disposable syringe
DE202006001995U1 (de) * 2006-02-07 2006-06-08 Sarstedt Ag & Co. Probengefäß zur Aufnahme von kleinen Flüssigkeitsmengen für Analysen
BRPI0710826A2 (pt) * 2006-04-21 2011-08-23 Novartis Ag composições farmacêuticas de anticorpo anti-cd40 antagonista
CN101541345A (zh) * 2006-09-25 2009-09-23 米迪缪尼有限公司 稳定化的抗体制剂和其应用
US20100209434A1 (en) * 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
SG10202000728UA (en) 2007-05-14 2020-03-30 Astrazeneca Ab Methods of reducing eosinophil levels
SG2014011365A (en) * 2008-09-19 2014-05-29 Hoffmann La Roche Novel antibody formulation
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
SG10201401995UA (en) * 2009-05-04 2014-08-28 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HK1200721A1 (en) * 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with xylitol
EP2771358A4 (en) * 2011-10-26 2015-08-26 Bio Rad Laboratories ELIMINATION OF VIRAL AGENTS IN MIXED MODE CHROMATOGRAPHY
CA2853823C (en) * 2011-10-28 2016-12-20 Integritybio Inc. Protein formulations containing amino acids
KR20140097217A (ko) * 2011-11-01 2014-08-06 메디뮨 엘엘씨 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법
KR20220057637A (ko) * 2013-08-12 2022-05-09 아스트라제네카 아베 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법
SMT201900311T1 (it) * 2013-08-12 2019-07-11 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
CN105611938B (zh) * 2013-10-24 2024-12-31 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品

Also Published As

Publication number Publication date
HUE055919T2 (hu) 2022-01-28
AU2025230794A1 (en) 2025-10-02
RU2016119755A (ru) 2017-11-27
US20150118249A1 (en) 2015-04-30
SG11201603206UA (en) 2016-05-30
CY1125697T1 (el) 2024-02-16
JP2019116480A (ja) 2019-07-18
JP6483673B2 (ja) 2019-03-13
HRP20211371T1 (hr) 2021-11-26
KR20210041101A (ko) 2021-04-14
LT3060229T (lt) 2021-09-27
CA2926089A1 (en) 2015-04-30
AU2022291595B2 (en) 2025-06-12
MX2021015825A (es) 2022-02-03
CA2926089C (en) 2022-08-30
CN113350278B (zh) 2023-03-24
US20250170245A1 (en) 2025-05-29
BR112016008576A2 (pt) 2017-10-03
KR102109053B1 (ko) 2020-05-13
PL3060229T3 (pl) 2021-12-27
CN105611938B (zh) 2024-12-31
JP2016535020A (ja) 2016-11-10
AU2014339984B2 (en) 2020-04-09
ES2893861T3 (es) 2022-02-10
AU2014339984A1 (en) 2016-04-28
PT3060229T (pt) 2021-10-07
EP3060229B1 (en) 2021-08-25
EP3060229A4 (en) 2017-08-16
US20190201535A1 (en) 2019-07-04
RU2021137159A (ru) 2022-01-11
KR20160068946A (ko) 2016-06-15
WO2015061584A1 (en) 2015-04-30
RU2763787C2 (ru) 2022-01-11
CN105611938A (zh) 2016-05-25
RS62419B1 (sr) 2021-10-29
RU2016119755A3 (da) 2018-04-28
EP3060229A1 (en) 2016-08-31
CN112107538A (zh) 2020-12-22
CN113350278A (zh) 2021-09-07
SI3060229T1 (sl) 2021-11-30
SG10201803178UA (en) 2018-05-30
SMT202100580T1 (it) 2021-11-12
EP3892288A1 (en) 2021-10-13
HK1221900A1 (zh) 2017-06-16
MX388893B (es) 2025-03-20
CN119971024A (zh) 2025-05-13
KR20200051844A (ko) 2020-05-13
AU2022291595A1 (en) 2023-03-16
MX2016004605A (es) 2016-11-14
AU2020204608A1 (en) 2020-07-30
BR112016008576B1 (pt) 2023-03-07
US20200297855A1 (en) 2020-09-24
JP6896781B2 (ja) 2021-06-30
JP2021152034A (ja) 2021-09-30
KR102238065B1 (ko) 2021-04-07

Similar Documents

Publication Publication Date Title
NO2021007I1 (no) calcifediol
DK3060229T3 (da) Stabile, vandige antistofformuleringer
CL2016000680A1 (es) Formulaciones de anticuerpos anti-pdl1.
EP3065716C0 (en) FORMULATIONS
FR3006466B3 (fr) .
DK3052080T3 (da) Langtidsvirkende spiro-isoxalin-formuleringer
EP2975063A4 (en) LOW SUBSTITUTED CELLULOSE ACETATE
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
HRP20171890T1 (hr) Supstituirani imidazopiridazini
DK2956698T3 (da) Bindestrimler
DK2975030T3 (da) Dihydropyridazin-3,5-dion-derivat
CL2014000227S1 (es) Decodificador
DK3044389T3 (da) Vinduespost-tværstykke-konstruktion
DK2946640T3 (da) Langmuir-probe
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DE102013106534B8 (de) Chromatographiepipettenspitze
EP3070792A4 (en) LASER
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
FR3001302B1 (fr) .
DK3071227T3 (da) Fiskevaccine
HUE050917T2 (hu) Hidrokortizon-tartalmú készítmény